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Amphiphilic polyanhydride-based recombinant MUC4β-nanovaccine
activates dendritic cells
Abstract
Mucin 4 (MUC4) is a high molecular weight glycoprotein that is differentially overexpressed in pancreatic
cancer (PC), functionally contributes to disease progression, and correlates with poor survival. Further, due
to its aberrant glycosylation and extensive splicing, MUC4 is a potential target for cancer immunotherapy.
Our previous studies have demonstrated the utility of amphiphilic polyanhydride nanoparticles as a useful
platform for the development of protein-based prophylactic and therapeutic vaccines. In the present study, we
encapsulated purified recombinant human MUC4-beta (MUC4β) protein in polyanhydride (20:80
CPTEG:CPH) nanoparticles (MUC4β-nanovaccine) and evaluated its ability to activate dendritic cells and
induce adaptive immunity. Immature dendritic cells when pulsed with MUC4β-nanovaccine exhibited
significant increase in the surface expressions of MHC I and MHC II and costimulatory molecules (CD80
and CD86), as well as, secretion of pro-inflammatory cytokines (IFN-γ, IL-6, and IL-12) as compared to cells
exposed to MUC4β alone or MUC4β mixed with blank nanoparticles (MUC4β+NP). Following
immunization, as compared to the other formulations, MUC4β-nanovaccine elicited higher IgG2b to IgG1
ratio of anti-MUC4β-antibodies suggesting a predominantly Th1-like class switching. Thus, our findings
demonstrate MUC4β-nanovaccine as a novel platform for PC immunotherapy.
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ABSTRACT
Mucin 4 (MUC4) is a high molecular weight glycoprotein that is differentially 
overexpressed in pancreatic cancer (PC), functionally contributes to disease 
progression, and correlates with poor survival. Further, due to its aberrant 
glycosylation and extensive splicing, MUC4 is a potential target for cancer 
immunotherapy. Our previous studies have demonstrated the utility of amphiphilic 
polyanhydride nanoparticles as a useful platform for the development of protein-
based prophylactic and therapeutic vaccines. In the present study, we encapsulated 
purified recombinant human MUC4-beta (MUC4β) protein in polyanhydride (20:80 
CPTEG:CPH) nanoparticles (MUC4β-nanovaccine) and evaluated its ability to activate 
dendritic cells and induce adaptive immunity. Immature dendritic cells when pulsed 
with MUC4β-nanovaccine exhibited significant increase in the surface expressions of 
MHC I and MHC II and costimulatory molecules (CD80 and CD86), as well as, secretion 
of pro-inflammatory cytokines (IFN-γ, IL-6, and IL-12) as compared to cells exposed 
to MUC4β alone or MUC4β mixed with blank nanoparticles (MUC4β+NP). Following 
immunization, as compared to the other formulations, MUC4β-nanovaccine elicited 
higher IgG2b to IgG1 ratio of anti-MUC4β-antibodies suggesting a predominantly 
Th1-like class switching. Thus, our findings demonstrate MUC4β-nanovaccine as a 
novel platform for PC immunotherapy.
INTRODUCTION
Pancreatic cancer (PC) has a dismal prognosis 
with an overall survival rate of 8%, due to the limited 
efficacy of existing treatment modalities including surgery, 
chemotherapy, and radiation [1, 2]. Furthermore, PC has 
an elaborate immunosuppressive microenvironment 
comprised of high desmoplasia, immune-suppressive cells 
and an anti-inflammatory cytokine milieu [3]. Due to the 
high level of chemotherapy-induced toxicity, PC patients 
seldom benefit from chemotherapy. Recent studies have 
shown that immunotherapy-based strategies like cancer 
vaccines can provide therapeutic benefit by breaking the 
immunological tolerance to self-derived tumor associated 
antigens (TAAs) and overcoming immunosuppression, 
thereby improving the overall survival and quality of 
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life [4, 5]. However, the development of efficacious anti-
cancer vaccines is arduous due to the challenges in finding 
TAAs, as the majority of these antigens behave as “self”, 
and therefore, are immunologically ignored by the host 
immune system [4]. 
Mucins are high molecular-weight glycoproteins 
that are overexpressed on various epithelial surfaces 
for protection and lubrication. Several mucins are 
aberrantly overexpressed in pancreatic cancer where 
they play tumor-promoting role. Due to their aberrant 
expression and glycosylation, functional involvement 
in the pathogenesis and correlation with poor prognosis, 
mucin family members have emerged as ideal TAAs 
for PC and are currently being exploited for cancer 
immunotherapy [6]. Mucin1 (MUC1) is one of the well-
studied targets for cancer vaccine development [7]. MUC1 
peptide and glycopeptide-based vaccine studies have 
shown their potential in eliciting anti-tumor responses 
in various malignancies [8-13]. However, the limited 
immunogenic epitopes provided by peptide-based MUC1 
vaccines have achieved suboptimal clinical success in PC 
patients [10, 14, 15]. Unlike MUC1, Mucin4 (MUC4) is 
undetectable in normal pancreatic tissue and its expression 
progressively increases with PC progression [16]. MUC4 
is putatively cleaved at a Gly-Asp-Pro-His (GDPH) site 
in an autocatalytic manner, generating two subunits: a 
large N-terminal subunit called MUC4α that contains 
the characteristic tandem repeat domain, and a smaller 
membrane-tethered subunit termed MUC4β [17-19]. The 
MUC4β region is considered functionally important as 
it has 3 EGF-like domains that interact with HER-2 and 
promote cancer cell proliferation [6, 19, 32]. In a previous 
study, it was shown that the mice immunized with MUC4 
glycopeptides conjugated to tetanus toxoid induced strong 
immune responses and predominantly produced IgG1 
antibodies [20]. However, such “cherry-picked” immuno-
dominant peptides limit the epitopes that can be employed 
to elicit immune responses in an unbiased manner, and 
thus are of limited translational value. While the large size 
of MUC4 can potentially provide a large epitope repertoire 
for eliciting potent immune responses, the production 
and purification of intact megadalton MUC4 protein is 
challenging. To circumvent these problems, this study 
investigated the utility of recombinant MUC4β subunit 
for tumor vaccine development. 
One of the major challenges of vaccine 
delivery vehicles is to ensure protein stability and 
release over a sustained period [21, 22]. Amphiphilic 
polyanhydride nanoparticles (NPs), composed of 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 
and 1,6-bis(p-carboxyphenoxy) hexane (CPH) have 
been shown to stabilize the structure and activity of 
encapsulated proteins while providing sustained release 
via a surface erosion mechanism [23, 24]. Furthermore, 
these NPs have been shown to be readily internalized by 
antigen presenting cells (APCs), such as dendritic cells 
(DCs) and macrophages, leading to the upregulation 
of cell surface activation markers including major 
histocompatibility complexes class I and II (MHC I and 
MHC II), co-stimulatory molecules (CD80, CD86, CD40), 
secretion of inflammatory cytokines and generation of 
humoral responses [25-28].
In the present study, we encapsulated endotoxin-free 
recombinant human MUC4β in 20:80 CPTEG:CPH NPs 
(MUC4β-nanovaccine). The relationships between antigen 
release kinetics, the ability of MUC4β-nanovaccine 
to activate APCs, and the nature of immune responses 
elicited were investigated. These studies demonstrated 
that the MUC4β-nanovaccine activated DCs, and 
induced a Th1 type of immune response. It was further 
observed that MUC4β-nanovaccine-immunized mice 
produced more IgG2b anti-MUC4β antibodies than IgG1 
antibodies, suggesting that MUC4β-nanovaccine induces 
sufficient IFN-γ to promote antibody isotype switching 
consistent with a Th1-like immune response. Therefore, 
the recombinant human MUC4β-based polyanhydride 
nanovaccine has the potential to be an effective 
immunotherapeutic modality against PC and other MUC4-
overexpressing malignancies.
RESULTS
Encapsulation of MUC4β into polyanhydride NPs 
provides sustained antigen release
The 20:80 CPTEG:CPH NPs loaded with 3% 
wt/wt MUC4β (endotoxin level < 0.01EU/mg) were 
synthesized via solid-oil-oil double emulsion. Scanning 
electron microscopy showed the NPs to be relatively 
spherical with a geometric mean diameter of 147 nm 
(with a geometric standard deviation of 1.3) (Figure 1A). 
The release kinetics of MUC4β from 20:80 NPs showed a 
burst of approximately 20% at early time points followed 
by slow and sustained release of protein (Figure 1B). The 
data showed that after four days, the 20:80 CPTEG:CPH 
particles released 23% of the encapsulated protein in 
a near-zero order release profile, which was consistent 
with previous work on protein release kinetics from 
CPTEG:CPH polyanhydride formulations [23, 24, 28-30]. 
Finally, the encapsulation efficiency of the MUC4β was 
determined to be 32 ± 1%. 
MUC4β-nanovaccine enhances the surface 
expression of MHC and co-stimulatory molecules 
on DCs
While the functional role of MUC4 in PC 
pathobiology has been studied extensively [16, 31-
38], the utility of MUC4 as a candidate for vaccine 
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development remains to be explored systematically. To 
examine the antigenicity of MUC4β and characterize the 
potential of MUC4β-nanovaccine in activating mature 
DCs, flow cytometry was used to measure the expression 
of cell surface markers such as MHC II and MHC I, co-
stimulatory molecules CD80 and CD86, CD40, and C-type 
lectin CD205 (DEC-205, a DC maturation marker). After 
9 days of IL-4 and GM-CSF treatment, more than 60% 
of the bone marrow-derived cells in culture differentiated 
into CD11c+ DCs. MUC4β-nanovaccine resulted in 
significantly higher activation of DCs as compared to 
other treatments as shown by the increased levels of 
costimulatory marker CD86 on the CD11c+ population 
(Figure 2A). There was no significant difference in the 
proportion of CD11c+CD86+ cells (activated DCs) across 
various treatments with the exception of cells treated 
with LPS as a positive control (Supplementary Figure 
1). However, an increase in mean fluorescence intensity 
(MFI) indicated that the MUC4β-nanovaccine upregulated 
DC activation markers on the CD11c+CD86+ population as 
compared to the unstimulated control and other treatment 
groups. On the CD11c+CD86+ gated cells, there was a 
significant upregulation of MHC I, CD80, and CD40 
following LPS treatment. As compared to the unstimulated 
control and other treatment groups (MUC4β alone, 
NP alone, and MUC4β+NP), treatment with MUC4β-
nanovaccine significantly enhanced the expression of 
MHC I, MHC II, and CD40 (Figure 2B-2E). As compared 
to unstimulated control, MUC4β-nanovaccine resulted in 
a 1.9-fold increase in MHC I and a 1.83-fold increase in 
MHC II on CD11c+CD86+cells (Figure 2B-2C). Similarly, 
there was a significant increase in the expression of 
CD80 on CD11c+CD86+ cells following treatment with 
MUC4β-nanovaccine (2.25-fold) and MUC4β+NP (1.76-
fold) as compared to untreated control, while treatment 
with MUC4β alone or blank NPs had no effect (Figure 
2D). Further, as compared to the unstimulated control, 
MUC4β-nanovaccine treatment significantly enhanced 
the surface expression of CD40 (1.72-fold; p < 0.001) 
on CD11c+CD86+cells, while there was no change 
following treatment with MUC4β alone, blank NP or 
MUC4β+NP (Figure 2E). Lastly, the expression of CD205 
was significantly upregulated on MUC4β-nanovaccine-
stimulated DCs (2.6-fold; p < 0.001) when compared to 
the unstimulated control group (Figure 2F). These results 
suggest that the MUC4β-nanovaccine upregulates MHC 
I, MHC II, and costimulatory molecules and promotes 
antigen presentation by DCs i in vitro. 
MUC4β-nanovaccine induces pro-inflammatory 
DC cytokine secretion
DCs direct immune responses not only by interacting 
with lymphocytes and presenting antigen [39, 40], but also 
by secreting an array of cytokines that modulate these 
responses. The supernatant of DCs cultured with MUC4β-
nanovaccine contained significantly higher levels of IL-
12p40, IL-6, and IFN-γ as compared to supernatants from 
untreated DCs or DCs stimulated with MUC4β alone or 
MUC4β+NP (Figure 3). The amounts of IL-6 and IL-12/
IL-23p40 in culture supernatants treated with MUC4β-
Figure 1: Encapsulation and release kinetics of MUC4β-nanovaccine. Endotoxin-free recombinant MUC4β protein was 
isolated from E. coli RosettaTM 2 (DE3) strain bacteria and purified by affinity chromatography. 20:80 CPTEG:CPH NPs encapsulating 3% 
MUC4β were synthesized via a solid/oil/oil double emulsion flash nanoprecipitation process. A. Scanning electron microscope images of 
20:80 CPTEG:CPH NP-encapsulated recombinant : MUC4β. B. Antigen release kinetics were characterized by incubating the NPs in PBS 
and measuring MUC4β released at regular intervals with a microBCA assay. 3% MUC4β-loaded 20:80 CPTEG:CPH NPs exhibited an 
initial burst (20%) release of protein followed by sustained release. The encapsulation efficiency of protein was determined to be ~32%.
Genes & Cancer4www.Genes&Cancer.com
nanovaccine were 2-fold and 1.5-fold higher, respectively, 
as compared to the unstimulated control (Figure 3A & 3B). 
The level of IFN-γ after MUC4β-nanovaccine treatment 
was found to be 1.25-fold higher than unstimulated control 
groups (Figure 3C). DCs treated with MUC4β alone or 
MUC4β+NP expressed low levels of cytokines, which 
were not significantly different than the levels expressed 
by unstimulated DCs. Similar to enhanced surface 
expression of MHC II and co-stimulatory molecules, DCs 
secreted higher levels of cytokines when treated with 
encapsulated MUC4β in 20:80 CPTEG:CPH NPs.
Immunization with MUC4β-nanovaccine elicits 
robust anti-MUC4 humoral responses
Polyanhydride nanovaccines have been shown to 
induce the formation of germinal center B-cells that result 
in sustained serum antibody responses after a single dose 
[41]. The presence of high levels of antigen-specific IgG2b 
Figure 2: MUC4β-nanovaccine activates DCs and induces expression of MHC II and co-stimulatory molecules. Flow 
cytometry analysis of in vitro antigen-pulsed DCs shows that MUC4β-nanovaccine activates DCs robustly as compared to other treatment 
groups. A. MUC4β-nanovaccine significantly upregulates CD86 expression in the CD11c+ population as analyzed by comparing the Mean 
Fluorescence Intensity (MFI) among all the treatment groups. LPS served as a positive control in the experiment, and unstimulated (US) 
DCs as negative control. B-F. Analysis of costimulatory and activation markers in CD11c+CD86+ cells. MUC4β-nanovaccine treatment 
upregulated the expression levels of MHC I (B), MHC II (C), CD80 (D), CD40 (E), and CD205 (F) after 48 h of stimulation 
using MUC4β protein (3 µg/mL), NP (100 µg/mL), or MUC4β+NP and MUC4β-nanovaccine (100 µg/mL). The fluorophore-conjugated 
antibodies were used at a 1:300 dilution except anti-CD40 antibody, which was used at a 1:200 dilution. The representative histograms for 
each surface marker have been presented with adjacent bar graphs showing the post-treatment MFI change. Each histogram plot represents 
a single experiment and the MFI plots summarize all experiments (n = 3). One-way ANOVA was used for data comparison for each group 
and pair wise comparison was performed using Student’s paired t-test. The statistical significance was set at p < 0.001. 
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over IgG1 indicates isotype-switching mediated by IFN-γ, 
whereas a low IgG2b:IgG1 ratio is indicative of Th2-like 
T-cell-response [42]. To investigate if immunization with 
MUC4β-nanovaccine induced robust humoral immune 
responses, animals were immunized subcutaneously 
twice (days 0 and 14) following the prime-boost 
regimen with MUC4β-nanovaccine or various control 
formulations (MUC4β emulsified in Freuend’s adjuvant 
or MUC4β free protein mixed with empty NPs). Five 
days after the booster, the anti-MUC4β titer was 16,000 
in the sera of mice that were immunized with the three 
formulations containing MUC4β. However, the reactivity 
was comparable and higher in mice administered with 
MUC4β emulsified in Freund’s adjuvant (FA) and 
MUC4β-nanovaccine as compared to the mice that 
received a mixture of free protein and blank NPs (Figure 
4A). Importantly, mice immunized with the MUC4β-
nanovaccine demonstrated a higher IgG2b:IgG1 ratio 
than mice immunized with MUC4β+FA (Figure 4B). 
These results indicate that MUC4β protein encapsulated 
in 20:80 CPTEG:CPH NPs predominantly elicits a Th1-
type immune response.
Immunization with MUC4β-nanovaccine 
enhances the circulating levels of inflammatory 
cytokines
Next, the presence of pro-inflammatory cytokines 
(IL-6, IL-12, and IFN-γ) in the sera of immunized mice 
was investigated. Sera from MUC4β-nanovaccine-
immunized mice had significantly higher levels of IL-6 
compared to MUC4β+FA- and MUC4β+NP-immunized 
mice (Figure 5A). The sera from MUC4β-nanovaccine-
immunized mice had significantly higher amounts of 
IL-12/IL-23p40 (~2.7-fold increase) and inflammatory 
cytokine IFN-γ (~5.2-fold increase) when compared to 
PBS-treated control mice (Figure 5B, 5C). Similarly, 
as compared to sera from the mice immunized with 
MUC4β+FA, we observed a significant increase of IL-12/
IL-23p40 (~2.2-folds) and IFN-γ (~4.5-folds) cytokines in 
the sera of MUC4β-nanovaccine-immunized mice (Figure 
5B, 5C). Significant upregulation of IFN-γ, as compared 
to control group as well as other treatment groups (Figure 
5C), suggests that MUC4β-nanovaccine promotes Th1 
mediated isotype switching of antibodies in these mice.
DISCUSSION
To date vaccine development involving mucins 
has been based on selected peptides that have a 
limited repertoire of immunogenic epitopes and have 
predominantly focused on the tandem repeat domains 
which are typically O-glycosylated. Recombinant proteins 
could address these limitations by presenting the entire 
spectrum of possible epitopes present in the original 
antigens in an unbiased manner [3]. In this study, the 
β-subunit of MUC4 expressed and purified from a bacterial 
expression system was used to investigate its potential as 
an effective immunogen. The data presented show that 
free MUC4β alone induces relatively low expression of 
MHC I and MHC II complexes, co-stimulatory molecule 
CD80 (Figure 2B-2D), and inflammatory cytokines in 
DCs (Figure 3A-3C) in vitro. Immunization of mice with 
MUC4β in combination with Freund’s adjuvant likely 
induces a Th-2 like response based on the induction of 
significantly higher levels of IgG1 antibodies (Figure 
4). Th2 immune responses have been well established to 
promote tumor pathogenesis and aggressiveness, whereas 
shifting the immune response to Th1 phenotype provides 
Figure 3: MUC4β-nanovaccine induces Th1 DC cytokine secretion. Cytokine analysis demonstrated that MUC4β-nanovaccine-
activated DCs secrete Th1 cytokines. Free MUC4β mixed with empty NPs (MUC4β+NP)-pulsed DCs and MUC4β -pulsed DCs produced 
Th1 cytokines at levels compared to the unstimulated (US) DCs. Only encapsulation of MUC4β could modulate and reprogram DCs to 
secrete higher levels of Th1 cytokines IL-6 (A), IL-12/IL-23p40 (B), and IFN-γ (C). For each treatment group, the sample size was n = 4. 
Statistical significance was set at p < 0.05. ANOVA analysis of the data was p < 0.05. Statistical comparison between MUC4β, MUC4β+NP 
and US with MUC4β-nanovaccine is denoted by #, * & + respectively.
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anti-tumor protection [43-45]. In this study, MUC4β 
was encapsulated into 20:80 CPTEG:CPH nanoparticles 
(MUC4β-nanovaccine) in order to investigate whether the 
MUC4β-nanovaccine could enhanced activation of DCs 
and modulated Th1-mediated humoral responses.
The MUC4β-nanovaccine enhanced surface 
expression of MHC I and MHC II on CD86+CD11c+ DCs 
(Figure 2B-2C), which are implicated in presentation of 
antigen, and increased the surface expression of CD80 
(Figure 2D), a co-stimulatory molecule required for 
activation T-cells. Antigen that is taken up via CD205 
enters the MHC I and MHC II antigen presentation 
pathways, and thus an increase in CD205 expression 
enhances antigen presentation by DCs to both CD8+ 
cytotoxic T-cells and CD4+ helper T-cells and could 
potentially lead to long-lived immunity by specifically 
targeting the cancer cells. [46, 47]. MUC4β-nanovaccine 
significantly enhanced surface expression of CD205 
on DCs (Figure 2F) that corresponded with increased 
expression of MHC complexes on these DCs. Thus, 
upregulation of these markers by MUC4β-nanovaccine, 
in comparison to free MUC4β-pulsed DCs, suggests that 
the encapsulated formulation was better in potentiating 
antigen presentation by DCs. Further, it was observed 
that only stimulation with MUC4β-nanovaccine enhanced 
DC secretion of the pro-inflammatory cytokines IL-6, IL-
12/IL-23p40, and IFN-γ in vitro (Figure 3) as compared 
to free MUC4β protein or MUC4β mixed with empty 
NPs (MUC4β+NP), which corroborated the observed 
alterations in the expression of DC activation markers. 
These results indicate that the encapsulation of MUC4β 
protein in CPTEG:CPH NPs is crucial in stimulating a 
cytokine profile that would enhance a Th1-like immune 
response. 
Previously, it has been shown that a single 
immunization of polyanhydride nanovaccines can induce 
high antibody titers and provide protective immunity 
against Yersinia pestis in mice [29, 48]. Additionally, 
it is important to consider the quality of the antibody 
response generated by the nanovaccine, which may be 
characterized by the specificity, avidity and isotype profile 
of the antibody response [49]. It is therefore noteworthy 
that the MUC4β-nanovaccine-immunized mice had the 
highest IgG2b:IgG1 ratio, which indicates induction 
of isotype class switching, whereas MUC4β+FA or 
MUC4β in combination with blank NPs preferentially 
induced IgG1 anti-MUC4β antibodies (Figure 4). This 
supports our in vitro observation that encapsulation of 
MUC4β into polyanhydride NPs likely plays a crucial 
role in activating DCs to produce cytokines (IL-6, IL-12/
IL-23p40 and IFN-γ) (Figure 3) that would polarize the 
immune response towards a Th1 phenotype. This was 
further validated with the detection of higher levels of 
IFN-γ in the sera of MUC4β-nanovaccine-immunized 
mice (Figure 5C). The data herein shows encapsulating 
MUC4β into 20:80 CPTEG: CPH NPs is an effective 
strategy to activate DCs and modulate the response 
towards an anti-MUC4 Th1 phenotype and potentially 
generate antigen-specific cytotoxic CD8+ T-cells. IgG2b 
antibodies may possibly provide additional immunity 
Figure 4: MUC4β-nanovaccine generates anti-MUC4β Th1 humoral response in mice. A. Titers of anti-MUC4β antibodies 
were determined by ELISA in the sera of mice immunized with various formulations, and suggest that MUC4β emulsified in Freund’s 
adjuvant (MUC4β +FA), or mixed with empty nanoparticles (MUC4β+NP), or encapsulated in the nanoparticles (MUC4β-nanovaccine)-
elicited anti-MUC4 antibodies. B. Isotyping of anti-MUC4β antibodies (at 1:1000 dilution) demonstrates that isotype switching was 
predominantly to Th1 IgG2b in MUC4β-nanovaccine-immunized mice, whereas in MUC4β-immunized mice it was predominantly the 
Th2 IgG1 isotype. For each treatment group sample size was n = 3. Statistical significance was set at p < 0.05. ANOVA analysis of the data 
was p < 0.05. Statistical comparison between MUC4β+FA and MUC4β-nanovaccine is denoted by #.
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against MUC4-expressing tumors by inducing antibody-
dependent-cellular cytotoxicity [50, 51]. The current 
studies provides a basis for investigating the use of the 
MUC4β-nanovaccine as an immunotherapeutic strategy 
in cancer models that overexpress MUC4 as a tumor-
associated antigen.
MATERIALS AND METHODS
MUC4β purification
The cDNA sequence encoding the 733 amino acids 
(2199 base pairs) of human MUC4β fragment was cloned 
into the bacterial expression vector pET-28a (Novagen, 
USA), and transformed into the E. coli RosettaTM 2 
(DE3) strain. Bacterial culture was grown under standard 
conditions and MUC4β was purified by AKTA Ni-
NTA affinity chromatography. Eluted fractions (in 6M 
urea) containing the recombinant MUC4β protein were 
assessed with SDS-PAGE gels and further confirmed with 
immunoblotting. All the verified fractions were pooled 
and concentrated using Amicon ultracentrifugal filters (50 
kDa molecular weight cut-off). A step-wise dialysis was 
performed against a decreasing concentration of urea in 
1Χ PBS to allow the protein refolding. Purified fractions 
were passed through an endotoxin removal spin column 
(Pierce). Finally, the concentration of our target protein 
and the level of endotoxins in the samples were measured 
using the BCA Protein Assay Kit (Pierce Thermo Fisher) 
and the Pierce LAL Chromogenic Endotoxin assay kit, 
respectively.
Encapsulation of MUC4β in polyanhydride 
nanoparticles
The 20:80 CPTEG:CPH polymer was synthesized 
via melt polycondensation [24]. Next the nanoparticles 
encapsulating MUC4β were synthesized using a solid-
oil-oil double emulsion technique as described previously 
[48]. Briefly, purified MUC4β was dialyzed to nanopure 
water and lyophilized. Next, 20:80 CPTEG:CPH polymer 
containing 3% wt. of MUC4β was dissolved at 20 mg/
mL in methylene chloride. The solution was sonicated 
for 30 s to ensure even distribution of the protein. The 
nanoparticles were precipitated into chilled pentane 
(-10°C; 1:250 methylene chloride: pentane) and collected 
via vacuum filtration. NP morphology was verified by 
scanning electron microscopy (FEI Quanta 250, FEI, 
Hillsboro, OR) and NP size subsequently analyzed with 
ImageJ (ImageJ 1.48v, NIH). 
The release kinetics of MUC4β from 20:80 
CPTEG:CPH nanoparticles were monitored as previously 
described [23]. Briefly, NPs were incubated in PBS 
at 37°C. Periodically, the samples were centrifuged, 
supernatant collected, and particles were resuspended 
in fresh buffer. The amount of protein in the collected 
supernatant was quantified using a microBCA assay. 
Further, the encapsulation efficiency was determined by 
comparing the total amount of protein released to the 
amount theoretically encapsulated. Briefly, at the end of 
approximately one month, the buffer was exchanged with 
40 mM sodium hydroxide to quickly degrade the NPs and 
release any remaining protein, which was estimated using 
microBCA assay. 
Figure 5: Presence of pro-inflammatory cytokines in the sera of mice immunized with MUC4β-nanovaccine. Levels 
of IL6 (A), IL-12 (B) and IFN-γ (C) in the sera of mice with immunied with various formulations. The sera of MUC4β-nanovaccine-
immunized mice had significantly higher levels of IL6, IL-12/IL23p40, and IFN-γ as compared to mice immunized with MUC4β+FA, and 
MUC4β+NP. For each treatment group, the sample size was n = 3. Statistical significance was set at p < 0.05. ANOVA analysis of the data 
was p < 0.05. Statistical comparison between MUC4β+FA, and MUC4β+NP with MUC4β-nanovaccine is denoted by # & * respectively.
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Primary dendritic cells (DCs) isolation
C57BL/6 mice were kept under specific pathogen-
free conditions at the UNMC Animal Facility in 
accordance with UNMC Institutional Animal Care 
and Use Committee (IACUC) standards. Femurs and 
tibiae of 6-8 week old C57BL/6 mice were removed 
and the marrow was flushed in RPMI medium using 
a 1 mL syringe attached to a 25 G needle. Cells were 
centrifuged at 2000 rpm for 2.5 min and the cell pellet 
was resuspended in 10 mL of 1x RBC lysis buffer in the 
dark for 5 min. Ten mL RPMI medium was added to stop 
the lysis. Cells were centrifuged at 2000 rpm and washed 
3 times in 10 mL of RPMI medium. After the last wash, 
cells were resuspended homogeneously in a 1 bone: 1 mL 
of media ratio. Resuspended cells were passed through 
a cell strainer to remove clumps. Cell suspensions were 
poured into 10 mL RPMI medium containing 10% FBS, 
penicillin (100 U/mL, Sigma) and streptomycin (100 
mg/mL, Sigma) in a 10 cm tissue culture plate that was 
then kept in an incubator for 3 h. After incubation, all 
nonadharent cells were collected and the plate was washed 
with medium twice to collect any remaining nonadharent 
cells into a 50 mL tube. The cells were pelleted down by 
centrifugation and the medium aspirated. The cells were 
resuspended in 10 mL complete RPMI medium containing 
50 µM β-merceptoethanol (β-ME), 1 mM sodium 
pyruvate, and 10 mM HEPES and transferred into T75 
flasks for our in vitro studies. 
DC maturation and pulsing
To generate bone marrow derived DC population, 
we added 50 ng/mL of recombinant mouse (rm) GM-CSF 
and 25 ng/mL rm-IL-4 reconstituted and diluted in serum-
free RPMI medium to freshly isolated DC cultures on 
Day 0. On Day 3, 5, and 7, the non-adherent cells were 
collected in 50 mL centrifuge tubes, pelleted them and 
re-suspended in a total volume of 10 mL of fresh RPMI 
medium containing 10% FBS, penicillin and streptomycin 
antibiotics, 10 mM HEPES, 1 mM sodium pyruvate, 50 
µM β- ME, 50 ng/mL of GM-CSF and 25 ng/mL IL-4 in a 
fresh 6-well plate. At Day 9, immature DCs were counted 
and seeded in a 24 well plate for activation studies. 
Polyanhydride NPs were suspended in complete culture 
medium, sonicated briefly (30 s on ice), and added to the 
DC cultures at Day 9 at a concentration of 100 μg/mL. 
DCs were pulsed in the following groups: 3 µg/mL free 
MUC4β protein, free MUC4β protein (3 µg/mL) mixed 
with blank NPs (100 μg/mL) (MUC4β+NP) and MUC4β-
nanovaccine (100 μg/mL). Unstimulated DCs (US) and 
DCs stimulated with LPS (200 ng/mL) were used as 
negative and positive controls, respectively. Cultures 
were incubated for 48 h (37°C, 5% CO
2
). Activated DCs 
were harvested from the 24-well plate and centrifuged at 
1000 x g for 5 min to collect the culture medium and the 
pellet was processed further for flow cytometry studies. 
Supernatant was collected for ELISA studies from each 
treatment group. 
Flow cytometry of activated DCs
DCs were resuspended and washed 3 times in FACS 
buffer containing 1xPBS (pH 7.2) and 1% fetal bovine 
serum (FBS) to remove any residual culture medium. 
After that, the 1X105 DCs were resuspended in a 100 µL 
volume of conjugated antibody cocktail for detection of 
DC surface markers consisting of antibodies recognizing 
CD11c, MHC I, MHC II, CD80, CD86, and CD205 and 
prepared at a 1:300 dilution except anti-CD40 antibody, 
which was used at 1:200 dilution in FACS Buffer. 
Corresponding isotype controls were also prepared at 
similar dilutions in FACS buffer. Following incubation 
with antibodies for 60 min on ice (4°C) in the dark, the 
cells were washed thrice with FACs buffer, and fixed with 
4% paraformaldehyde for 15 min at RT. The cells were 
washed again and analyzed using a BD LSR-II Green 
Flow Cytometer (BD Biosciences). FlowJo® and BD 
FACSDIVA software were used to analyze the data.
Cytokine analysis by ELISA
Supernatants were preserved at -80°C. IL-6, IFN-γ 
and IL-12/IL-23 p40 cytokines were measured by enzyme-
linked immunosorbent assay (ELISA) kits from BioLegend 
and the manufacturer’s protocol was followed for the 
assay. 96-well ELISA strips were coated with capture 
antibodies (1:200 dilution) in carbonate-bicarbonate buffer 
(0.5M, pH 9.6) and incubated overnight at 4°C. The next 
day coated strips were washed 4 times with 1xPBST (1x 
PBS and 0.05% Tween 20) and blocked with 3% bovine 
serum albumin (BSA) in PBS for 2 hours at 37°C. Strips 
were then washed 4 times and 100 µL of supernatants were 
added to coated strips and incubated for 2 hours at 37°C. 
Plates were washed with PBST for 4 times, followed by 
incubation with detection antibody (1:200) for 1 hour at 
37°C. Excess secondary antibody was washed away with 
4 PBST washes. Avidin (1:1000) was added to ELISA 
strips and incubated for 30 min at RT in dark. Excess 
avidin was removed with 5 PBST washes, followed 
by addition of TMB (3,3’,5,5’-Tetramethylbenzidine) 
substrate in the dark and the strips were incubated at RT 
for color to develop. Absorbance was measured after the 
reaction was stopped (~15 min) with 1N H
2
SO
4
 at 450 
nm using a SpectraMax® Plus384 microplate reader 
(Molecular Devices LLC, Sunnyvale, California). For 
serum cytokines analysis, serum samples were collected 
post-euthanasia and stored at -80°C. Serum samples were 
added at 1:10 dilution to capture-antibody coated plates 
for cytokine analysis. 
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Mice immunization
Eight-week old C57BL/6 mice were immunized 
subcutaneously with various formulations of recombinant 
MUC4β protein emulsified with Freund’s incomplete 
adjuvant (MUC4β+FA: 20 µg/mouse/dose), encapsulated 
MUC4β protein (MUC4β-nanovaccine: 20 µg 
protein+300 µg NP/mouse/dose), protein plus empty 
NPs (MUC4β+NP: 20 µg MUC4β+300 µg empty NP /
mouse/dose), and PBS+ Freund’s adjuvant control. 
A booster immunization was given 2 weeks after the 
primary immunization and blood was collected from the 
submandibular vein after 5 days and processed for serum 
preparation. 
Anti-MUC4β antibodies detection in immunized 
mice sera by ELISA
To detect anti-MUC4β antibodies in the sera of 
immunized mice, we used a modified ELISA protocol. A 
96-well plate was coated with 5 μg/mL of recombinant 
MUC4β protein in carbonate-bicarbonate coating buffer 
(0.5 M, pH 9.6) and incubated overnight at 4°C. The plate 
was washed 2 times with 1xPBST and blocked with 3% 
BSA in PBS for 3 hours at 37°C. Further, the plate was 
washed 4 times and then serial dilutions of the serum 
samples were incubated in a MUC4β-coated plate for 2 
hours at 37°C. Plates were washed with PBST 4 times, 
followed by incubation with horseradish-peroxidase 
(HRP) conjugated goat anti-mouse IgG (total H+L) 
(Thermo Fisher), IgG1 (Abcam) or IgG2b (Abcam) for 
1 hour at 37°C. Excess secondary antibody was washed 
away with 5 PBST washes followed by the addition of 
TMB substrate in the dark. Absorbance was measured 
after the reaction was stopped (at ~15 min) with 1N H
2
SO
4
 
at 450 nm using a SpectraMax® Plus384 microplate 
reader (Molecular Devices LLC, Sunnyvale, California).
Antibodies
Alexa Fluor® 700 anti-mouse CD11c (clone N418), 
anti-Mouse MHC Class I (H-2Kb) eFluor® 450 (Clone: 
AF6-88.5.5.3), FITC conjugated anti-mouse/rat MHC 
Class II (I-A/I-E; clone M5/114.15.2), APC anti-mouse 
CD40 (clone 1C10), PE conjugated anti-mouse CD80 
(clone 16-10A1) antibodies with their respective isotype 
controls comprising of Alexa Fluor® 700 conjugated 
Armenian hamster IgG (clone eBio299Arm), FITC rat 
IgG2b κ (clone eB149/10H5), Rat IgG2a k Isotype Control 
APC (clone eBR2a), PE-conjugated rat IgG2a (clone 
eBR2a), Rat IgG2a k Isotype Control PE-Cyanine7 (clone 
eBR2a), and mouse IgG2a k Isotype Control eFluor® 
450 (clone eBM2a) were purchased from eBioscience™ 
(San Diego, CA). PE/Cy7™ rat anti-mouse CD86 (Clone 
GL1) was purchased from BD Pharmingen™. PE/Cy 5.5 
anti-mouse CD205 (MMR, clone NLDC-145) and PerCP/
Cy5.5 Rat IgG2a, κ Isotype control were procured from 
BioLegend®.
Statistical analysis
Differences among group means were tested by one-
way analysis of variance (ANOVA) F-test using GraphPad 
Prism v. 7.0 (GraphPad, La Jolla, CA). If the F-test was 
significant, Tukey’s t-tests were performed for pairwise 
comparisons of group means. Significance was defined at 
p < 0.05 or p < 0.001 as indicated in the respective figure 
legends. 
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